Filing Flows › Editas Medicine (EDIT) › Q2 2026 › vs Q1 2026
Editas Medicine (EDIT) Q2 2026 vs Q1 2026 (quarter over quarter)
Editas Medicine's revenue rose $9.1M (+320%) from $2.8M in Q1 2026 to $11.9M in Q2 2026.
Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%, net loss $18.2M, operating cash flow −$29.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $11.9M | $2.8M | $9.1M | +320% |
| Other income, net | $324K | $21K | $303K | 15× |
| Net loss | $18.2M | $25.0M | −$6.8M | -27% |
| Costs & expenses | $30.4M | $27.8M | $2.6M | +9% |
| Operating costs | $30.4M | $27.8M | $2.6M | +9% |
| Operating cash sources | $32.2M | $25.6M | $6.5M | +25% |
| Depreciation | $416K | $483K | −$67K | -14% |
| Share-based compensation | $2.2M | $2.1M | $91K | +4% |
| Cash used in operations | $29.6M | $23.1M | $6.5M | +28% |
| Net loss absorbed | $18.2M | $25.0M | −$6.8M | -27% |
| Working capital & other | $13.9M | $664K | $13.3M | 21× |
Questions
How much did Editas Medicine's revenue grow quarter over quarter in Q2 2026?
Editas Medicine's revenue rose $9.1M (+320%) from $2.8M in Q1 2026 to $11.9M in Q2 2026.